Actinium to Present Full Results from Pivotal Phase 3 Trial on Call Following Presentation

  Late-breaker presentation at 5:00 PM EST on Saturday, February 18, 2023, to feature Iomab-B SIERRA Pivotal Trial results

-  Investor call at 6:00 PM EST on Saturday, February 18, 2023, to highlight full results from the Phase 3 SIERRA trial

Actinium Pharmaceuticals, Inc.,  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies, today announced its presence at the upcoming Tandem Meetings: Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) being held February 15 – 19, 2023 at the World Center Marriott in Orlando, Florida. Actinium will host an investor conference call and webcast to present full topline results from its pivotal Phase 3 SIERRA trial of Iomab-B at 6:00 PM EST on Saturday, February 18, 2023. The investor conference call will follow the late-breaker presentation of the full Phase 3 SIERRA trial results. In addition, Iomab-B will be highlighted in a CME Event titled, "The Convergence of Innovative Therapy and AlloHCT in AML: Applying Current Evidence to Improve Outcomes Across Patient Populations.

Investor Conference Call and Webcast Details:

Time / Date:	6:00 PM EST on Saturday, February 18, 2023
Presenters:	Sandesh Seth, Chairman & CEO, Madhuri Vusirikala M.D., Vice President, Clinical Development – Transplant & Cellular Therapy, Avinash Desai, M.D., Chief Medical Officer, Caroline Yarbrough, Chief Commercial Officer
Dial-in:	1-877-407-0784 (toll-free domestic) or 1-201-689-8560 (international) or by clicking on this link and requesting a return call
Live webcast:	To access the live webcast of the call with slides please visit the Investors section of Actinium's website https://ir.actiniumpharma.com/presentations-webinars or https://viavid.webcasts.com/starthere.jsp?ei=1590226&tp_key=580722640c

An archived webcast will be available on the Actinium's website (click here) after the event.

https://www.biospace.com/article/releases/actinium-to-present-full-results-from-pivotal-phase-3-iomab-b-sierra-trial-on-investor-call-following-the-late-breaker-presentation-at-the-2023-transplantation-and-amp-cellular-therapy-tandem-meetings-on-saturday-february-18-2023/